お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙:MELFLUFEN:新しいALアミロイドーシス治療薬の分析・予測 (~2030年)
市場調査レポート
商品コード
974757

MELFLUFEN:新しいALアミロイドーシス治療薬の分析・予測 (~2030年)

MELFLUFEN- Emerging Insight and Market Forecast - 2030

出版日: 受注後作成 | 発行: DelveInsight Business Research LLP | ページ情報: 英文 60 Pages | 納期: 2~10営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=109.72円
MELFLUFEN:新しいALアミロイドーシス治療薬の分析・予測 (~2030年)
出版日: 受注後作成
発行: DelveInsight Business Research LLP
ページ情報: 英文 60 Pages
納期: 2~10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

ALアミロイドーシス治療薬の市場は世界中での広範な研究と医療費の増加により、今後数年で規模を拡大する見通しであり、医薬品メーカーはより多くの市場に参入できるようになると予測されています。

当レポートでは、新しいALアミロイドーシス治療薬であるMELFLUFENの主要7カ国 (米国・ドイツ・フランス・イタリア・スペイン・英国・日本) における展望を調査し、製品概要、作用機序、臨床開発・臨床試験の動向、関連法規制、特許動向、売上予測、競合状況、SWOT分析、アナリストの見解などをまとめています。

第1章 薬剤の概要

  • 製品概要
  • 作用機序
  • 投薬・管理
  • R&D活動
    • 臨床開発
    • 安全性・有効性
  • その他の開発活動

第2章 市場評価

  • 主要7ヶ国市場の分析
  • 米国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • 英国
  • 日本

第3章 SWOT分析

第4章 アナリストの見解

第5章 競合事業者

第6章 他の新しい治療薬

第7章 付録

第8章 購入オプション

図表

List of Tables

  • Table 1 MELFLUFEN, Description
  • Table 2 MELFLUFEN, Clinical Trial Description
  • Table 3 MELFLUFEN, 7MM Market Size from 2020 to 2030 (in Million USD)
  • Table 4 Market Competitors
  • Table 5 Other Emerging Therapies

List of Figures

  • Figure 1 The Development Timeline of MELFLUFEN
  • Figure 2 Patent Details, MELFLUFEN
  • Figure 3 MELFLUFEN, 7MM Market Size from 2020 to 2030 (in Million USD)
  • Figure 4 MELFLUFEN, US Market Size from 2020 to 2030 (in Millions USD)
  • Figure 5 MELFLUFEN, EU5 Market Size from 2020 to 2030 (in Millions USD)
  • Figure 6 MELFLUFEN, Japan Market Size from 2020 to 2030 (in Millions USD)
目次
Product Code: DIDM0138

"MELFLUFEN- Emerging Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for AL Amyloidosis in 7 Major Markets. A detailed picture of the MELFLUFEN in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020-2030 is provided in this report along with a detailed description of the product. The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.

Overview:

Melflufen is an anticancer drug under development by Oncopeptides AB. It is a peptidase enhanced cytotoxic that exerts a targeted delivery of melphalan in cells with high expression of aminopeptidases, such as aminopeptidase N, which has been described as over-expressed in human malignancies.

Scope of the report:

The report provides insights into:

  • A comprehensive product overview including the product description, mechanism of action, dosage and administration, Research and Development activity.
  • Elaborated details on regulatory milestones and other development activities have been provided in this report.
  • The report also highlights the drug research and development activity details across the United States, Europe and Japan.
  • The report also covers the patents information with expiry timeline around MELFLUFEN.
  • The report contains forecasted sales for MELFLUFEN till 2030.
  • Comprehensive coverage of the late-stage emerging therapies (Phase II) for AL Amyloidosis.
  • The report also features the SWOT analysis with analyst insights and key findings of MELFLUFEN.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

MELFLUFEN Analytical Perspective by DelveInsight

  • In-depth MELFLUFEN Market Assessment

This report provides a detailed market assessment of MELFLUFEN in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.

  • MELFLUFEN Clinical Assessment

The report provides the clinical trials information of MELFLUFEN covering trial interventions, trial conditions, trial status, start and completion dates.

Report highlights:

  • In the coming years, the market scenario for AL Amyloidosis is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence MELFLUFEN dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Other emerging products for AL Amyloidosis are giving market competition to MELFLUFEN and launch of late-stage emerging therapies in the near future will significantly impact the market.
  • A detailed description of regulatory milestones, development activities, and some key findings provide the current development scenario of MELFLUFEN.
  • Our in-depth analysis of the forecasted sales data of MELFLUFEN from 2020 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the MELFLUFEN.

Key Questions:

  • Which company is developing MELFLUFEN along with the phase of the clinical study?
  • What is the technology utilized in the development of MELFLUFEN?
  • What is the product type, route of administration and mechanism of action of MELFLUFEN?
  • What is the clinical trial status of the study and study completion date?
  • What are the key collaborations, mergers and acquisitions, licensing and other activities related to the MELFLUFEN development?
  • What are the key designations that have been granted to MELFLUFEN?
  • What is the forecasted market scenario of MELFLUFEN?
  • What is the history of MELFLUFEN and what is its future?
  • What is the forecasted sales of MELFLUFEN in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
  • What are the other emerging products available and how these are giving competition to MELFLUFEN?
  • Which are the late-stage emerging therapies under development for the treatment of the PPD?

Table of Contents

1. Drug Overview

  • 1.1. Product Detail
  • 1.2. Mechanism of Action
  • 1.3. Dosage and Administration
  • 1.4. Research and development activity
    • 1.4.1. Clinical Development
    • 1.4.2. Safety and Efficacy
  • 1.5. Other Development Activities

2. Market Assesment

  • 2.1. 7MM Market Analysis
  • 2.2. The United States Market
  • 2.3. Germany Market
  • 2.4. France Market
  • 2.5. Italy Market
  • 2.6. Spain Market
  • 2.7. United Kingdom Market
  • 2.8. Japan Market

3. SWOT Analysis

4. Analyst Views

5. Market Competitors

6. Other Emerging Therapies

7. Appendix

8. Report Purchase Options

株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.